 Celldex Therapeutics Incs NASDAQ: CLDX shares closed almost 16 down on Friday after releasing Phase 1b study data of barzolvolimab. Cantor says the main reason for stock being down is the four patient adverse events on the generally transient, asymptomatic, and mild. 